Intuitive Surgical (ISRG)

Intuitive’s business model extends beyond the initial sale or placement of its robotic systems. The company generates recurring revenue from instruments, accessories, service contracts, and warranties used with installed systems. This creates a durable ecosystem around each da Vinci platform, as hospitals and surgical teams continue to purchase disposable and reusable components as procedure volumes grow. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with a large installed base in the United States and expanding adoption in international and emerging markets.

The company is widely regarded as a pioneer and market leader in robotic-assisted surgery. Its competitive strengths include a large clinical user base, extensive training infrastructure, accumulated procedure data, and a long operating history in a highly regulated healthcare market. Intuitive’s growth is influenced by hospital capital spending, surgeon adoption, procedure expansion, reimbursement conditions, and competition from other surgical robotics platforms. For investors, the stock represents exposure to the long-term shift toward technology-enabled surgery and the increasing use of robotics in operating rooms.